DE69915478D1 - Geschmacksmaskierung mittels croscarmellose - Google Patents

Geschmacksmaskierung mittels croscarmellose

Info

Publication number
DE69915478D1
DE69915478D1 DE69915478T DE69915478T DE69915478D1 DE 69915478 D1 DE69915478 D1 DE 69915478D1 DE 69915478 T DE69915478 T DE 69915478T DE 69915478 T DE69915478 T DE 69915478T DE 69915478 D1 DE69915478 D1 DE 69915478D1
Authority
DE
Germany
Prior art keywords
croscarmellose sodium
croscarmellose
preparing
taste
bitter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69915478T
Other languages
English (en)
Other versions
DE69915478T2 (de
Inventor
Michael Augello
M Dell
E Reier
J Stamato
Lynn M Dimemmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RP Scherer Technologies LLC
Original Assignee
RP Scherer Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RP Scherer Technologies LLC filed Critical RP Scherer Technologies LLC
Publication of DE69915478D1 publication Critical patent/DE69915478D1/de
Application granted granted Critical
Publication of DE69915478T2 publication Critical patent/DE69915478T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE1999615478 1998-07-08 1999-07-08 Geschmacksmaskierung mittels croscarmellose Expired - Lifetime DE69915478T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9199698P 1998-07-08 1998-07-08
US91996P 1998-07-08
US09/330,445 US6099865A (en) 1998-07-08 1999-06-11 Croscarmellose taste masking
US330445 1999-06-11
PCT/US1999/015510 WO2000002536A1 (en) 1998-07-08 1999-07-08 Croscarmellose taste masking

Publications (2)

Publication Number Publication Date
DE69915478D1 true DE69915478D1 (de) 2004-04-15
DE69915478T2 DE69915478T2 (de) 2005-01-13

Family

ID=26784551

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999615478 Expired - Lifetime DE69915478T2 (de) 1998-07-08 1999-07-08 Geschmacksmaskierung mittels croscarmellose

Country Status (9)

Country Link
US (1) US6099865A (de)
EP (1) EP1094788B1 (de)
AT (1) ATE261299T1 (de)
CA (1) CA2336570C (de)
DE (1) DE69915478T2 (de)
DK (1) DK1094788T3 (de)
ES (1) ES2217774T3 (de)
PT (1) PT1094788E (de)
WO (1) WO2000002536A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2461354C (en) * 2001-09-28 2010-04-27 Mcneil-Ppc, Inc. Fondant-based pharmaceutical composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009503A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1673064A1 (de) * 2003-08-28 2006-06-28 Sandoz AG Pharmazeutische zusammensetzung mit einem antikonvulsivum mit geschmacksüberdeckendem überzug
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) * 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
WO2011056702A2 (en) * 2009-10-28 2011-05-12 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
US20110150993A1 (en) * 2009-12-22 2011-06-23 Fmc Corporation Fine Particle Croscarmellose and Uses Thereof
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
WO2014184663A2 (en) * 2013-05-15 2014-11-20 Apr Applied Pharma Research Sa Orally dispersible drug formulations
WO2017192921A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3130058B2 (ja) * 1991-02-15 2001-01-31 第一製薬株式会社 マスクされた粒状物
ATE245023T1 (de) * 1991-05-28 2003-08-15 Mcneil Ppc Inc Kaubare zusammensetzung zur arzneimittelfreisetzung
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
CA2184361C (en) * 1994-03-24 2000-12-05 Francis Bernard Chapura Solid dose forms containing bismuth
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
CA2336570A1 (en) 2000-01-20
WO2000002536A1 (en) 2000-01-20
ES2217774T3 (es) 2004-11-01
PT1094788E (pt) 2004-07-30
ATE261299T1 (de) 2004-03-15
EP1094788A4 (de) 2003-04-02
DK1094788T3 (da) 2004-08-16
EP1094788B1 (de) 2004-03-10
DE69915478T2 (de) 2005-01-13
CA2336570C (en) 2009-04-14
EP1094788A1 (de) 2001-05-02
US6099865A (en) 2000-08-08

Similar Documents

Publication Publication Date Title
DE69915478D1 (de) Geschmacksmaskierung mittels croscarmellose
DE60129573D1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
ES2081349T3 (es) Rotogranulaciones y recubrimientos para enmascarar el sabor para la preparacion de comprimidos farmaceuticos de mascar.
HUP0203168A2 (hu) Készítmények nyálkahártyán át történő beadásra
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HUP0203728A2 (hu) Formoterolt tartalmazó aeroszolkészítmény
ATE265205T1 (de) Feste arzneimittel enthaltend trehalose
WO2002047607A3 (en) Process for the preparation of a fast dissolving dosage form
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
NO20052408D0 (no) Farmasoytisk formulering av olanzapin
DK0765157T3 (da) Pellets
BG107157A (en) Sustained release beadlets containing stavudine
AP1595A (en) Pharmaceutical formulation having a masked taste and method for the production thereof.
JPS5883618A (ja) ニトロフラントイン投与剤
JPH10504295A (ja) 医薬処方
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
CA2429793A1 (en) Interferon therapeutic effect enhancer
HUP0102052A2 (hu) Pelletek, amelyek magja lipidszintcsökkentő hatóanyaggal és egy polimerrel van bevonva és eljárás az előállításukra
MD984B1 (ro) Tabletă de ranitidină avînd acoperire şi procedeu de obţinere a acestei acoperiri
HUP0100398A2 (hu) Eljárás gyógyászati készítmény előállítására
JP4221299B2 (ja) フィルム錠剤製造用リバビリン顆粒
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition